Appendix 2—table 40. Antidiabetic Non-user Cohort (All Regions) by BP Use, Patient Characteristics Pre/Post Match of BP Users/Non-users.
| All Antidiabetic Non-users by BP: Unmatched | All Antidiabetic Non-users by BP: Matched | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All | BP Non-user | BP User | p-value | All | BP Non-user | BP User | p-value | |||||||
| N | % | N | % | N | % | N | % | N | % | N | % | |||
| All Patients | 754,553 | 100.0% | 681,380 | 90.3% | 73,173 | 9.7% | 145,028 | 100.0% | 72,514 | 50.0% | 72,514 | 50.0% | ||
| Age | ||||||||||||||
| ≤20 | 6,211 | 0.8% | 6,199 | 0.9% | 12 | 0.0% | <0.001 | 24 | 0.0% | 12 | 0.0% | 12 | 0.0% | 1.00 |
| 21-40 | 57,723 | 7.6% | 57,497 | 8.4% | 226 | 0.3% | 455 | 0.3% | 229 | 0.3% | 226 | 0.3% | ||
| 41-50 | 91,905 | 12.2% | 90,693 | 13.3% | 1,212 | 1.7% | 2,421 | 1.7% | 1,209 | 1.7% | 1,212 | 1.7% | ||
| 51-60 | 191,196 | 25.3% | 180,332 | 26.5% | 10,864 | 14.8% | 21,721 | 15.0% | 10,860 | 15.0% | 10,861 | 15.0% | ||
| 61-70 | 207,435 | 27.5% | 180,825 | 26.5% | 26,610 | 36.4% | 53,115 | 36.6% | 26,558 | 36.6% | 26,557 | 36.6% | ||
| 71-80 | 138,310 | 18.3% | 114,018 | 16.7% | 24,292 | 33.2% | 47,723 | 32.9% | 23,861 | 32.9% | 23,862 | 32.9% | ||
| ≥81 | 61,773 | 8.2% | 51,816 | 7.6% | 9,957 | 13.6% | 19,569 | 13.5% | 9,785 | 13.5% | 9,784 | 13.5% | ||
| Gender | ||||||||||||||
| Female | 458,455 | 60.8% | 393,376 | 57.7% | 65,079 | 88.9% | <0.001 | 128,836 | 88.8% | 64,411 | 88.8% | 64,425 | 88.8% | 0.91 |
| Male | 296,098 | 39.2% | 288,004 | 42.3% | 8,094 | 11.1% | 16,192 | 11.2% | 8,103 | 11.2% | 8,089 | 11.2% | ||
| Region | ||||||||||||||
| Midwest | 134,022 | 17.8% | 123,283 | 18.1% | 10,739 | 14.7% | <0.001 | 21,390 | 14.7% | 10,695 | 14.7% | 10,695 | 14.7% | 1.00 |
| Northeast | 217,040 | 28.8% | 197,710 | 29.0% | 19,330 | 26.4% | 38,510 | 26.6% | 19,255 | 26.6% | 19,255 | 26.6% | ||
| South | 289,781 | 38.4% | 261,382 | 38.4% | 28,399 | 38.8% | 55,812 | 38.5% | 27,906 | 38.5% | 27,906 | 38.5% | ||
| West | 113,710 | 15.1% | 99,005 | 14.5% | 14,705 | 20.1% | 29,316 | 20.2% | 14,658 | 20.2% | 14,658 | 20.2% | ||
| Insurance | ||||||||||||||
| Commercial | 307,022 | 40.7% | 289,018 | 42.4% | 18,004 | 24.6% | <0.001 | 35,983 | 24.8% | 17,988 | 24.8% | 17,995 | 24.8% | 1.00 |
| Dual | 42,603 | 5.6% | 33,444 | 4.9% | 9,159 | 12.5% | 17,221 | 11.9% | 8,611 | 11.9% | 8,610 | 11.9% | ||
| Medicaid | 206,875 | 27.4% | 190,166 | 27.9% | 16,709 | 22.8% | 33,264 | 22.9% | 16,636 | 22.9% | 16,628 | 22.9% | ||
| Medicare | 198,053 | 26.2% | 168,752 | 24.8% | 29,301 | 40.0% | 58,560 | 40.4% | 29,279 | 40.4% | 29,281 | 40.4% | ||
| PCP Visit 2019 | ||||||||||||||
| No | 252,752 | 33.5% | 233,775 | 34.3% | 18,977 | 25.9% | <0.001 | 37,812 | 26.1% | 18,903 | 26.1% | 18,909 | 26.1% | 0.97 |
| Yes | 501,801 | 66.5% | 447,605 | 65.7% | 54,196 | 74.1% | 107,216 | 73.9% | 53,611 | 73.9% | 53,605 | 73.9% | ||
| Continuous Outcomes | ||||||||||||||
| mean | SD | mean | SD | mean | SD | p-value | mean | SD | mean | SD | mean | SD | p-value | |
| CCI | 1.24 | 1.82 | 1.24 | 1.81 | 1.24 | 1.89 | 0.92 | 1.24 | 1.87 | 1.24 | 1.87 | 1.25 | 1.88 | 0.63 |
BP: bisphosphonate; CCI: Charlson Comorbidity Index; PCP: primary care physician; SD: standard deviation.